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Objectives 
The aim of this study was to determine the extent to which structural damage, clinical 
disease activity, demographic and social factors are associated with work disability 
(WD) in psoriatic arthritis (PsA). 
 
Methods 
Four hundred patients fulfilling CASPAR criteria for PsA were recruited from 23 
hospitals across the UK.  Demographic, socioeconomic, work, clinical and 
radiographic data were collected.  WD was assessed with the WPAI-SHP reporting 
work disability as percentage of absenteeism (work time missed), presenteeism 
(impairment at work/reduced effectiveness) and work productivity loss (overall work 
impairment/absenteeism plus presenteeism).  Logistic and linear regressions were 
conducted to investigate associations with WD  
 
Results 
Two hundred and thirty six participants of any age were in work.  Absenteeism, 
presenteeism and productivity loss rates were 14% (SD 29.0), 39% (SD 27.2) and 
46% (SD 30.4) respectively.  Ninety two (26%) participants of working age were 
unemployed.  Greater age, disease duration of 2 to 5 years and worse physical 
function were associated with unemployment.  Patient reported employer awareness 
and helpfulness exerted a strongly positive influence on remaining in employment.  
Higher levels of global and joint specific disease activity and worse physical function 
were associated with greater levels of presenteeism and productivity loss amongst 
those who remained in work. 
 
Conclusion 
Reduced effectiveness at work was associated with measures of disease activity 
whereas unemployment, considered the endpoint of work disability, was associated 
with employer factors, age and disease duration. Longitudinal study is underway to 
determine whether treatment to reduce disease activity ameliorates work disability in 
the real world setting. 
  
Introduction 
Psoriatic Arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis.  
Patients with PsA may have skin and joint disease but may also have manifestations 
such as enthesitis, axial disease, uveitis, the metabolic syndrome and other less well 
defined factors related to long term inflammation such as fatigue.  All these elements 
combine to have a significantly detrimental effect on physical function and quality of 
life.1  Work is of central importance to patients and it is now well recognised that 
work disability (WD) is an important, patient centred quality of life outcome that 
needs further investigation.2  WD is an umbrella term encompassing a spectrum of 
disability including productivity loss, presenteeism (reduced effectiveness at work), 
through to absenteeism and unemployment.  
 
The existing body of knowledge relating to WD in PsA has been recently reviewed.3  
There is evidence suggesting that levels of unemployment (20-50%) and WD (16-
39%) are high and associated with longer disease duration, worse physical function, 
high joint count, low educational level, female sex, erosive disease and manual work. 
Interpretation of this data is hampered by the small number of reports, heterogeneity 
of data collected and the limitations of post hoc analyses of work data as a secondary 
endpoint.3  The current body of evidence comes either from short duration, highly 
selected randomised controlled trials (RCT’s) with limited generalizability or registry 
databases relating to employment levels or disability benefit collection.  
We set out to determine to what extent structural damage, clinical disease activity, 
demographic and social factors are associated with employment, absenteeism, 
presenteeism, and productivity loss in psoriatic arthritis using the work productivity 
and activity impairment measure (WPAI).4  
 
Methods 
Long Term Outcome in Psoriatic arthritiS II (LOPAS II) is a multicentre 
observational cohort study conceived to explore the associations with WD in PsA and 
study the effect of drug treatment.  Twenty three sites across England participated in 
this study.  Four hundred patients fulfilling CASPAR criteria for PsA commencing a 
new DMARD or anti-TNF treatment were recruited and baseline data have been used 
to investigate factors associated with WD.   
 
Demographic information on sex, education, smoking and alcohol use, ethnicity, 
disease and symptom duration and number and type of co-morbidities was collected 
using a background information form.  The following outcome data was collected at 
the routine clinic visits: physician assessment of disease activity was made with the 
disease activity in psoriatic arthritis composite score DAPSA (summation of 66 
swollen and 68 tender joint count, C-reactive protein (CRP), patient global and pain 
visual analogue scores (VAS) summed together)5, patient reported outcomes included 
physical function with the  health assessment questionnaire (HAQ), the European 
quality of life five domain questionnaire (EQ5D), dermatology quality of life index 
(DLQI), global and domain specific activity VAS scores and the functional 
assessment of chronic illness therapy (FACIT fatigue).  Work disability was assessed 
with the WPAI, a patient-reported quantitative assessment of the amount of 
absenteeism, presenteeism, productivity loss and general activity impairment 
attributable to a specific health problem. Additional work data was collected on a 
questionnaire designed for this study including job title (converted into the 
international standard classification of occupational 2008 (ISCO-08), employer 
awareness/helpfulness on a Likert scale.  Radiographs of the hands and feet were 
taken and scored using the psoriatic arthritis Ratingen score.6  
 
Statistical analysis 
Statistical analysis of demographic data has been undertaken in SPSS v20.  
Associations between potential explanatory variables and unemployment status were 
examined using multivariate logistic regression and with per cent presenteeism and 
productivity loss using multivariate linear regression models.  The distribution of 
absenteeism showed small numbers in a number of categories and was converted into 
a binary variable representing either present (0%) or absent (100%) and analysed 
using multivariate logistic regression. The regression analyses were undertaken using 
the statistical package R (2011). All measured variables were considered for 
inclusion, including location.  Age demonstrated a non-linear relationship therefore a 
quadratic term was applied.  Two way interactions were considered in all models but 
no significant effects at this level were observed. 
 
 
 
Results 
Of the four hundred participants three hundred and eighteen were of UK working age 
(18-65 years), mean age 46.8 years (sd 11.02), mean disease duration 5.8 years (sd 
8.00), 49.9% female.  Two hundred and twenty six participants of working age 
participants (64%) were in work with a further ten over retirement age still working.  
Ninety two participants of working age (26%) were unemployed.  Comparison of 
demographic, clinical, radiographic and socioeconomic factors of those working (any 
age) and those not working (18 -65 years only) are presented in table 1.  The mean 
level of absenteeism, presenteeism and productivity loss of the 236 participants in 
work was 14% (sd 29.0), 39% (sd 27.2) and 46% (sd 30.4) respectively.  
 
Negative influences upon remaining in employment included greater age, duration of 
two to five years and worse physical function (Table 2). For every additional year of 
age the risk of unemployment increased by 1%, Odds Ratio (OR) of 0.99 (95% CI 
0.994 to 0.999, p=0.02).  Disease duration of 2 to 5 years exerted a strongly negative 
influence upon remaining in employment OR 0.41 (95% CI 0.180-0.953 p=0.03).  
The association of worse physical function with unemployment was strong such that 
the risk of unemployment increased by OR 0.56 (0.343 – 0.926, p=0.02) for every 
increase in HAQ score by 1 (HAQ score 0-3).  Finally employer helpfulness exerted a 
strongly positive influence on remaining in employment.  If participants rated an 
employer as helpful the likelihood of employment was increased by an OR of 15.10 
(95% CI 4.658-69.355, p=<0.01).  This positive effect was sustained even if the 
participant perceived that no help was required, OR 3.22 (95% CI 1.264-8.229, 
p<0.01).  
 
Absenteeism as a binary variable (present or absent over the prior week) was 
associated with worse joint activity visual activity scale (0-100) such that for every 
increase of 10 on the VAS scale the OR of absenteeism increased by 4% (OR 1.04 
(95% CI 1.018-1.055, p=<0.01).  
 
Greater global, joint specific disease activity and worse physical function exerted a 
negative influence on presenteeism and productivity loss (Table 2).  For every 
increase in global disease activity visual analogue scale (0-100) of 10 there was an 
increase of presenteeism of 2% (estimate 0.02, 95% CI 0.001-0.053, p=0.01) and 3% 
for productivity loss (estimate 0.03, 95% CO 0.003-0.55, p=0.01).  Worse physical 
function (HAQ scale 0-3) was strongly associated with more presenteeism and 
productivity loss.  For every increase in HAQ of 1 presenteeism was 47% higher 
(estimate 0.63, 95% CI 0.005-1.200, p=0.03) and productivity loss 12% higher 
(estimate 0.12, 95% CO 0.066-0.182, p<0.01). 
 
Discussion 
We report the associations of unemployment, absenteeism, presenteeism and 
productivity loss amongst a well classified cohort of patients with PsA recruited from 
multiple sites across England. 
 
With regards to unemployment we report the novel findings that patient reported 
employer helpfulness, greater age and recent disease onset are associated with 
unemployment.  The British Society of Rheumatologists Biologics Register (BSRBR) 
is the only study to date to investigate the influence of age upon employment and did 
not find an association.7 In this present study the absolute effect of each year of age 
upon becoming unemployed is small, an increase of 1% for every additional year of 
age.  PsA is however a chronic disease and when considered over decades this effect 
becomes a clinically meaningful burden.  
 
The finding in our present study of increased unemployment in those with early 
disease (two to five years duration) is an interesting one and in keeping with the 
finding of high levels of unemployment in the first five years of rheumatoid arthritis 
reviewed by Nikiphorou et al.8,  Four studies have previously reported that increasing 
disease duration negatively influences remaining in employment.7, 9-11 The findings of 
this present study of increased unemployment in those with disease duration of 2-5 
years does differ from these prior reports and the differences in study designs may 
account for this.  First, the mean disease duration of patients in this study was 8 years, 
substantially less than the one other study conducted in the UK, the BSRBR study 
(14years)7.  Second, differing social security systems may influence an individual’s 
decision to stop work and three of the other prior studies were conducted in countries 
other than the UK; Germany10 Norway11 and Sweden9.  Finally we have measured 
relatively short duration absenteeism with the WPAI which has a recall period of one 
week whereas other studies were based on government social security benefit 
collection records thus measuring more long-term absence from work. 
 
To our knowledge this is the first time patient reported employer helpfulness has been 
investigated in PsA.  We have found that and employer awareness and helpfulness on 
remaining in employment exerts a positive influence, even if patients perceive no help 
is required.  This finding emphasises the multifactorial influences upon WD and the 
importance of accounting for as many potentially confounding factors as possible.  
The strength of this association in the regression model may account for variables 
identified in previous studies such as worse physical function7, 11, 12, joint disease7, 12, 
13, fatigue12, erosive disease11, sex7, 9, 11 and education10, 11 not achieving significant 
associations and subsequent inclusion into the final models.  
 
Relating to absenteeism, presenteeism and productivity loss amongst those at work we 
report that only disease activity factors rather than demographic or socioeconomic 
factors influence performance.  Specifically in this present study greater global, joint 
specific disease activity and worse physical function exerted a negative influence on 
presenteeism and productivity loss.  Furthermore disease activity measures appear to 
exert a greater influence than severity (radiographic damage), which did not achieve 
inclusion into the final models. This suggests that although there are multiple 
potential social and economic influencing factors disease activity remains an 
important influencing factor.  
 
The finding that global and joint specific activity but not the domain of skin disease 
(skin specific activity VAS score or DLQI) reached statistical significance in the final 
models is consistent with prior reports comparing patients with PsA and those with 
psoriasis alone.  Two studies have reported increased WD amongst patients with PsA 
versus patients with psoriasis alone.14, 15  To our knowledge this is the first study 
reporting the relative impact of joint and skin disease on WD and indicates that joint 
disease exerts the greatest influence in this cohort.  It should be noted that the level of 
skin activity compared to joint activity was low (39% skin VAS versus 62% joint 
VAS amongst those not working). By including people with relatively mild skin 
disease we may have overestimated the relative influence of the joint domain.  
Nonetheless the finding in this study that disease activity measures, which are 
potentially reversible, exert a negative influence upon performance at work adds 
strength to the theory that presenteeism/ productivity loss can be improved with 
treatment.  
 
The findings of this study should be interpreted in light of certain methodological 
considerations. First, the twenty three recruiting centres were located across England 
though did not include London, potentially limiting the generalisability of the results. 
We did employed a spatial model to assess for geographic variation in WPAI however 
and no differences were detected. Second, we have previously reported low levels of 
agreement between joint count assessors in this study which will have reduced our 
ability to detect any association with WD.16 Training in joint count assessment was 
subsequently given to recruiting centres in an attempt to standardise clinical 
assessment. Finally it should be noted that the employer helpfulness Likert scale was 
developed for use in this study and has not been formally validated. 
 
In conclusion greater age, recent disease onset (2 to 5 years disease duration) and 
worse physical function exert a negative influence on remaining in employment.  
Patient reported employer awareness and helpfulness exerts a strongly positive 
influence on remaining in employment, even if patients perceive no help is required.  
In contrast in those who remain at work reduced effectiveness (presenteeism and 
productivity loss) are associated with the disease activity measures of greater global, 
joint specific visual analogue scales and worse physical function.  Further prospective 
study is underway to investigate whether ameliorating disease activity improves 
absenteeism, presenteeism and productivity loss.  
 
 
Key points: 
 Presenteeism and productivity loss are associated with measures of greater 
disease activity. 
 Unemployment is associated with employer helpfulness, age, disease duration 
and physical function. 
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